Bright Minds Biosciences
DRUG
6 hedge funds and large institutions have $208K invested in Bright Minds Biosciences in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.51% less ownership
Funds ownership: 4.94% → 4.43% (-0.51%)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
77% less capital inflows, than outflows
Capital inflows: $5.59K | Capital outflows: $24.7K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AdvisorShares Investments
Bethesda,
Maryland
|
+$5.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21.4K |
| 2 |
Jane Street
New York
|
-$3.22K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$115 |
DRUG Hedge Fund Activity: Q2 2024 in Review
6 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q2 2024, worth a combined $208K — down 19% from $256K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DRUG and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was AdvisorShares Investments, adding an estimated $5.59K. The largest seller was Citadel Advisors, exiting entirely with an estimated $21.4K sold.
- 6 institutional investors held Bright Minds Biosciences (DRUG) as of Q2 2024, down from 7 in Q1 2024.
- Funds reported $208K of Bright Minds Biosciences stock for Q2 2024, down 19% quarter-over-quarter.
- 0 funds opened new Bright Minds Biosciences positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest Bright Minds Biosciences buyer in Q2 2024 was AdvisorShares Investments, an estimated $5.59K added.
- The largest Bright Minds Biosciences seller in Q2 2024 was Citadel Advisors, an estimated $21.4K sold.
Based on aggregated 13F filings for Q2 2024.